Danaher: Strong Buy Signal
Analysts Maintain 'Buy' Ratings on Danaher Amid Price Target Adjustments, See Undervalued Stock
Anonymous
Key Points
1
TD Cowen has maintained a Buy rating on Danaher with a price target of 236, signaling continued optimism despite recent target revisions.
2
Danher's diversified portfolio includes notable brands such as Beckman Coulter and Dexis, underscoring its broad exposure within the healthcare equipment and diagnostics space.
3
Danaher has a market capitalization of about $123.96 billion, highlighting its status as a large-cap player in the healthcare sector.
4
GuruFocus notes a GF Score for Danaher, which ranks stocks on a 0-100 scale based on five key factors to assess investment quality.
5
Danaher operates in the Medical Diagnostics & Research segment of the healthcare sector, reflecting its core area of focus beyond other business lines.
Wall Street analysts are trimming their price targets on Danaher (NYSE: DHR) while still calling the stock a buy. Benzinga reports that Guggenheim cut its target from $235 to $200 — a 14.89% reduction — but kept its Buy rating. Stifel and TD Cowen followed suit, lowering targets to $220 and $236, respectively, while holding firm on their bullish calls.
Not everyone is cutting. Benzinga also reports that RBC Capital bucked the trend and raised its price target to $215, maintaining an Outperform rating. The moves come as Danaher trades near $176, well below most analyst targets, suggesting the market may be underpricing the stock.
Analysts Cut Targets But Keep Their Buy Ratings
Guggenheim's cut to $200 is the most aggressive reduction among the firms. GuruFocus notes the firm slashed its target by nearly 15%, from $235 to $200. Despite the drop, analysts still see meaningful upside from current trading levels near $176. That gap between the stock price and the lowest target is about 14%.
TD Cowen kept a target of $236, the highest among the group. Benzinga reported the firm maintained its Buy stance even as it lowered expectations. Stifel set its target at $220, also holding a Buy. All three firms are signaling caution about near-term conditions while betting on long-term strength.
RBC Raises Its Target as Others Pull Back
RBC Capital stands out from the crowd. While peers were cutting, RBC raised its price target to $215 and kept an Outperform rating, according to Benzinga. An Outperform rating means RBC expects Danaher to do better than the broader market. The raise signals growing confidence in the company's core business.
Danaher operates in medical diagnostics and research. Its portfolio includes well-known brands like Beckman Coulter and Dexis. The company's focus on healthcare equipment gives it stable, recurring demand. That may be why RBC sees more reason for optimism than its peers right now.
Valuation Data Points to a Potential Discount
GuruFocus analysis suggests Danaher may be undervalued by about 26%. The site's GF Value — a proprietary fair-value estimate — sits near $238 per share. With the stock trading around $176, that implies a significant gap. GF Value uses historical multiples, past growth, and future earnings estimates to set its benchmark.
Danaher's price-to-earnings (P/E) ratio is 34.11x, just below its five-year median of 36.02x, according to GuruFocus. A P/E below the historical average can signal a cheaper entry point. With a market cap of roughly $123.96 billion, Danaher remains one of the largest players in the healthcare sector. The data collectively supports the analyst view that the stock is trading at a discount.
What the Target Revisions Signal for Danaher's Outlook
Price-target cuts often reflect broader market caution, not necessarily company-specific problems. In Danaher's case, analysts appear to be adjusting for a tougher macro environment while keeping faith in the business itself. Every firm that revised its target still rates the stock as a Buy or Outperform.
The range of targets — from $200 to $236 — still sits well above the current trading price of around $176. That means even the most conservative analyst sees roughly 14% upside from here. The consensus is clear: the stock may have near-term headwinds, but the long-term case for Danaher remains intact.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
23
Reach
35
A
AnonymousAuthor